Vera Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Vera Therapeutics, Inc. (VERA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-10
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.30%, a 0.00% change year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.10%, a 8.89% decline year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.10%, a 6.82% decline year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.30%, a 6.52% decline year-over-year.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 2.17% decline from fiscal 2024.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 2.13% decline from fiscal 2023.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.70%, a 11.90% increase from fiscal 2022.
- Vera Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 223.08% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-10 | 4.30% 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | 4.10% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.50% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-05 | 4.50% 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 4.30% 10-Q · filed 2026-08-10 | 4.50% 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.60% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-05 | 4.60% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-05 | 4.60% 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 4.70% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.20% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-08 | 4.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.00% 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | 4.20% 10-K · filed 2024-03-27 | |||
| 2022-09-30 | 4.10% 10-Q · filed 2023-11-09 | 4.10% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 3.10% 10-Q · filed 2023-08-10 | 3.10% 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 1.90% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 1.30% 10-K · filed 2023-03-28 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-09 | 1.10% 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-10 | 1.10% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 0.80% 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 1.67% 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 1.70% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-16 | 1.70% 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | 1.70% 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |